» Articles » PMID: 37966669

Establishment and Characterization of a Novel Hilar Cholangiocarcinoma Cell Line, CBC3T-1

Overview
Journal Hum Cell
Publisher Springer
Specialty Cell Biology
Date 2023 Nov 15
PMID 37966669
Authors
Affiliations
Soon will be listed here.
Abstract

Cholangiocarcinoma (CCA) is a group of malignant heterogeneous cancer arising from the biliary tree. The tumor is characterized by insidious onset, high degree of malignancy, poor prognosis, and high recurrence rate. Immortalized cancer cell lines are the best and easiest models for in vitro cancer research. Here, we established a naturally immortalized highly tumorigenic hilar cholangiocarcinoma (hCCA) cell line, CBC3T-1. The CBC3T-1 cell line was cultured for over 60 passages. Thorough analysis showed that CBC3T-1 cells share characteristics similar to original tumor cells from patients with cholangiocarcinoma and display a stable phenotype, including features of epithelial origin, stem cell-like properties, as well as a high invasive and migratory capability and tumorigenicity in mice. Furthermore, this cell line showed the best sensitivity to paclitaxel, followed by gemcitabine. RNA sequencing and whole‑exome sequencing showed that cancer-associated pathways and somatic mutations played a dominant role in the development of CCA. We established and characterized a new hCCA cell line, CBC3T-1, which contributes to a better understanding of bile duct cancer, and can be used to study tumorigenesis and progression and the role of anticancer drugs.

Citing Articles

Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6.

Bai M, Wang R, Huang C, Zhong R, Jiang N, Fu W Sci Rep. 2024; 14(1):29661.

PMID: 39613883 PMC: 11607416. DOI: 10.1038/s41598-024-81392-0.

References
1.
Feng N, Huang X, Jia Y . Mycoplasma contamination affects cell characteristics and decreases the sensitivity of BV2 microglia to LPS stimulation. Cytotechnology. 2019; 71(2):623-634. PMC: 6465415. DOI: 10.1007/s10616-019-00311-8. View

2.
Banales J, Inarrairaegui M, Arbelaiz A, Milkiewicz P, Muntane J, Munoz-Bellvis L . Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology. 2018; 70(2):547-562. PMC: 6767196. DOI: 10.1002/hep.30319. View

3.
Shi T, Gong J, Fujita K, Nishiyama N, Iwama H, Liu S . Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo. Int J Oncol. 2021; 58(2):199-210. PMC: 7864011. DOI: 10.3892/ijo.2020.5165. View

4.
Bergquist A, von Seth E . Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015; 29(2):221-32. DOI: 10.1016/j.bpg.2015.02.003. View

5.
Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A . Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 173(2):371-385.e18. PMC: 6029450. DOI: 10.1016/j.cell.2018.02.060. View